Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RAB11B antisense RNA 1 (RAB11B-AS1)
- Target
- RAB11B-AS1
- Molecular classification
- Other (long non-coding RNA, SINEUP RNA, antisense transcript)
01
Overview
RAB11B antisense RNA 1 (RAB11B-AS1) is a long non-coding RNA overlapping the RAB11B gene in antisense orientation. It is notable as a naturally occurring SINEUP molecule, with functional domains essential for upregulating RAB11B protein translation in human neuronal progenitors and other cell types. RAB11B-AS1's expression is sensitive to CHD8 levels, which are important for neurodevelopment and associated with autism risk. Its dysregulation may contribute to ASD pathogenesis by affecting vesicular trafficking and synaptic activity. RAB11B-AS1 is also upregulated under hypoxia in cancer, suggesting roles in tumoral adaptation and progression. Evidence indicates variable regulatory effects in different cancer types and cell contexts (upregulating, downregulating, or neutral). RAB11B-AS1 serves as a host gene for microRNA-4999, further linking it to complex RNA-mediated regulatory networks.
- Other names
- MIR4999HGMIR4999 host geneRAB11B antisense RNA 1 (non-protein coding)RAB11B-AS1
02
Mechanism of action
Not applicable—RAB11B-AS1 acts as a regulator (SINEUP) by increasing translation of RAB11B protein rather than serving as a direct drug target
03
Biological functions
Regulation of protein translation (post-transcriptional upregulation of RAB11B protein)Modulation of synaptic vesicle trafficking, potentially through RAB11BResponse to hypoxia in cancer cells (upregulated by HIF-2α)
04
Disease associations
Cancer (breast cancer, hepatocellular carcinoma, lung cancer, osteosarcoma; implicated in tumor progression and hypoxic response)Neurodevelopmental disorders (potential involvement in Autism Spectrum Disorders through interactions with CHD8 and regulation of brain development genes)
05
Safety considerations
None specific to RAB11B-AS1 as a molecular target; therapeutic modulation remains unexplored and may pose challenges common to RNA therapeutics (off-target effects, delivery)
06
Biomarkers
Possible role as a biomarker in Autism Spectrum Disorders and cancer (expression level changes relevant in disease context, especially hypoxia adaptation in tumors)
Beyond the preview
Go deeper on RAB11B antisense RNA 1 (RAB11B-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAB11B antisense RNA 1 (RAB11B-AS1).